TransCode Therapeutics, Inc.
RNAZ
$1.78
-$0.11-5.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -57.84% | -47.16% | -127.23% | -109.19% | 17.61% |
| Total Depreciation and Amortization | 78.36% | -53.32% | -63.55% | -96.24% | -90.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.42% | 11.10% | 188.41% | 102.20% | -74.36% |
| Change in Net Operating Assets | 566.28% | 615.82% | -63.85% | 118.44% | -114.35% |
| Cash from Operations | -28.80% | -60.75% | -158.78% | -4.36% | -79.26% |
| Capital Expenditure | -- | -- | -1,240.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -780.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 226.52% | -118.62% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.15% | -186.45% | 280.61% | -206.95% | -169.02% |